Tirzepatide (Zepbound): SURMOUNT-5 trial Tirzepatide is a dual GLP-1/GIP receptor agonist that builds on single-hormone agents by targeting an additional pathway for enhanced satiety
Options for managing tolerance include a brief dose reduction for 4 to 8 weeks ("drug holiday" at a lower dose, not complete cessation), lifestyle optimization to maximize the medication effect, evaluation for other contributing factors (thyroid function, cortisol, sleep quality, medication interactions), and consideration of adding a complementary compound to address specific aspects of the plateau
Mong rng vi nhng gi trn, bn c th la chn cho mnh sn phm ph hp vi mnh
Increased Fluids Increasing fluid intake is essential for managing constipation, diarrhea, nausea, and vomiting
Your weight loss and how you feel should remain unaffected
In this way, we can get information about how people come to us